A double-blind, randomised, single-centre, placebo-controlled, cross-over phase I study to investigate renal function in healthy male subjects, after repeated oral dosing of 3 mg AZ 242

Study identifier:SH-SBC-0022

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A double-blind, randomised, single-centre, placebo-controlled, cross-over phase I study to investigate renal function in healthy male subjects, after repeated oral dosing of 3 mg AZ 242

Medical condition

Diabetes Mellitus

Phase

Phase 1

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Aug 2002
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

-

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria